“We can’t take the orphan drug revolution for granted.“ Biorasi’s Few & Far Between Podcast welcomes Jim Geraghty, author and biotech industry veteran, to discuss the necessity and viability of orphan and rare disease research - for both patients and VC investors alike.
Is the epigenome the "software" of the cell nucleus? Find out in our latest episode of the Biorasi Few & Far Between podcast! Host...
On today’s podcast, Jimmy El Hokayem, Head of the Neurology and Regenerative Medicine Centers of Excellence and Associate Director of Program Development at Biorasi,...
"I hope we're moving into the age of the generalist, where knowing how to learn and learning how to learn are more important than...